# Staar Surgical Company (STAA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.43B  
**Price:** $28.90 (-1.47%)

> Staar Surgical Company designs, develops, manufactures, and sells implantable lenses for eye surgery, operating primarily in the ophthalmic medical devices sector. The company offers two main product categories: Implantable Collamer lenses (ICL) used in refractive surgery to correct vision problems without removing the eye's natural lens, and intraocular lenses (IOL) used in cataract surgery. Staar Surgical delivers these products through specialized accessory delivery systems designed for surgical use. With over 2.5 million implants performed worldwide, the company serves ophthalmic surgeons and surgical centers globally. The ophthalmic surgical product segment generates the majority of Staar Surgical's revenue. Founded in 1982 and headquartered in Lake Forest, California, Staar Surgical operates as a medical device manufacturer focused on vision correction and cataract treatment solutions for healthcare providers and patients seeking surgical vision correction alternatives.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $239M | $182M | -$92M | -$80M | $-1.62 |
| 2024 | $314M | $240M | -$13M | -$20M | $-0.41 |
| 2023 | $322M | $253M | $28M | $21M | $0.43 |
| 2022 | $239M | $223M | $44M | $40M | $0.80 |
| 2021 | $230M | $179M | $33M | $28M | $0.56 |
| 2021 | $22M | $118M | $7M | $6M | $0.12 |
| 2020 | $21M | $112M | $12M | $14M | $0.30 |
| 2018 | $23M | $92M | $7M | $5M | $0.11 |
| 2017 | $22M | $64M | -$4M | -$2M | $-0.05 |
| 2016 | $23M | $58M | -$13M | -$12M | $-0.30 |
| 2016 | $77M | $53M | -$5M | -$7M | $-0.17 |
| 2015 | $75M | $49M | -$8M | -$8M | $-0.22 |
| 2014 | $72M | $50M | $700,000 | $398,000 | $0.01 |
| 2012 | $64M | $44M | -$1M | -$2M | $-0.05 |
| 2011 | $63M | $42M | $3M | $1M | $0.04 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2026 | $452M | $107M | $344M | $153M | — |
| 2024 | $510M | $112M | $397M | $144M | — |
| 2023 | $489M | $103M | $386M | $183M | — |
| 2022 | $419M | $83M | $336M | $86M | — |
| 2021 | $346M | $87M | $262M | $200M | — |
| 2021 | $257M | $60M | $197M | $152M | — |
| 2020 | $208M | $48M | $160M | $120M | — |
| 2018 | $167M | $35M | $132M | $104M | — |
| 2017 | $68M | $25M | $43M | $19M | — |
| 2016 | $65M | $28M | $38M | $14M | — |
| 2016 | $63M | $24M | $39M | $13M | — |
| 2015 | $59M | $22M | $37M | $13M | — |
| 2014 | $62M | $23M | $39M | $23M | — |
| 2012 | $55M | $23M | $32M | $22M | — |
| 2011 | $49M | $20M | $29M | $17M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2026 | -$34M | $6M | -$40M |
| 2024 | $16M | $23M | -$8M |
| 2023 | $15M | $18M | -$4M |
| 2022 | $36M | $18M | $18M |
| 2021 | $44M | $14M | $30M |
| 2021 | $21M | $8M | $13M |
| 2020 | $26M | $10M | $16M |
| 2018 | $13M | $2M | $11M |
| 2017 | $3M | $1M | $2M |
| 2016 | $1M | $3M | -$2M |
| 2016 | -$2M | $2M | -$4M |
| 2012 | $3M | $2M | $946,000 |
| 2011 | $5M | $962,000 | $4M |
| 2010 | -$4M | $320,000 | -$5M |
| 2010 | $1M | $553,000 | $874,000 |

Source: [CompaniesByCap](https://companiesbycap.com/company/STAA)